Cargando…
Reduced work absenteeism in patients with hepatitis C treated with second‐generation direct‐acting antivirals
The cost‐effectiveness of the second‐generation direct‐acting antivirals (DAA) has received considerable attention; however, their effect on wider societal costs has remained relatively unexplored. The aim of this study was to investigate the effect the new drugs have on sick leave compared to older...
Autores principales: | Lindgren, Peter, Löfvendahl, Sofia, Brådvik, Gunnar, Weiland, Ola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756207/ https://www.ncbi.nlm.nih.gov/pubmed/32896927 http://dx.doi.org/10.1111/jvh.13398 |
Ejemplares similares
-
Value appropriation in hepatitis C
por: Lindgren, Peter, et al.
Publicado: (2021) -
Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
por: Frisk, P., et al.
Publicado: (2018) -
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12
por: Werner, Christoph R, et al.
Publicado: (2016) -
Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019) -
Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)